Sermorelin is often marketed as a gentle, "natural" way to boost growth hormone. It also has a real FDA history, which makes it different from many peptides sold online. Here is what happened to sermorelin, how it works, and where it stands today.
Key takeaways
- Sermorelin is a short, lab-made piece of GHRH, the brain's natural signal for growth hormone release.
- It was FDA-approved as Geref: first as a diagnostic test, later to treat GH deficiency in children with growth failure.
- The maker discontinued Geref in 2008, and FDA withdrew the approvals in 2009. FDA later said this was not for safety or effectiveness reasons.
- There is no currently marketed FDA-approved sermorelin product in the US.
- Evidence for anti-aging or body composition use in healthy adults is limited.
What sermorelin is
Natural GHRH is a chain of 44 amino acids. Researchers found that the first 29 amino acids carry the activity. Sermorelin is that 29-amino-acid piece, sometimes written GHRH (1-29).
Like other GHRH analogs, sermorelin binds to receptors on pituitary cells and signals them to release growth hormone (GH). Your body's normal brakes, such as somatostatin and feedback from IGF-1, still apply. That is why sermorelin is often described as working "with" your natural rhythm. It still raises GH, and GH has effects beyond the ones people want.
A short history
According to FDA's 2013 Federal Register notice:
| Year | Event |
|---|---|
| 1990 | Geref (sermorelin) ampule approved as a diagnostic test of the pituitary's ability to release GH |
| 1997 | Geref vials approved to treat idiopathic GH deficiency in children with growth failure |
| 2008 | The maker, EMD Serono, notified FDA it was discontinuing both products |
| 2009 | FDA withdrew approval of both applications, effective June 18, 2009 |
| 2013 | FDA determined the products were not withdrawn for reasons of safety or effectiveness |
That last step matters for regulators. Because the products were not pulled for safety, FDA said it could approve generic versions that reference Geref, if other legal requirements are met. As of this writing, we are not aware of a currently marketed FDA-approved sermorelin product.
The notice does not say why the maker stopped selling Geref. You may see online claims about the reason. Treat those as opinions unless they cite the company or FDA.
Where it stands now
Today in the US, sermorelin shows up in three main ways:
- Compounded prescriptions. Some licensed compounding pharmacies prepare sermorelin for an individual patient's prescription. Compounded drugs are not FDA-approved, meaning FDA has not reviewed that product for safety, effectiveness or quality. The rules for which ingredients can be compounded are technical. Our guide to 503A vs. 503B pharmacies explains the basics.
- "Research use only" products. These are not made for human use, and quality can vary widely. PepSteady does not recommend them.
- Clinical research. Researchers have studied it in small trials over the years.
Because the law and FDA policy can change, ask your prescriber and pharmacist how a specific product is made and regulated.
What the evidence shows
The strongest evidence for sermorelin comes from its approved history: children with GH deficiency and pituitary testing. Those uses were studied enough for approval in their time.
For adults, the picture is much thinner. Small, older studies looked at sermorelin in aging adults and found it could raise GH and IGF-1. Effects on body composition, strength, sleep or well-being were inconsistent, and the studies were small and short. There are no large, modern trials showing that sermorelin slows aging, improves long-term health or is safe for years of use in healthy adults.
That is the honest summary: it does what it was designed to do, which is raise GH. Whether that helps a healthy adult, and at what risk, is not well established.
Possible side effects and cautions
Reported side effects with sermorelin and similar GHRH analogs include:
- Injection site pain, redness or swelling
- Flushing or headache
- Dizziness or nausea
- Effects related to higher GH and IGF-1, such as fluid retention or changes in blood sugar
General cautions for GH-raising treatments apply. People with active cancer, uncontrolled diabetes, pituitary problems or who are pregnant need a careful conversation with a specialist. A provider who prescribes sermorelin should check baseline labs such as IGF-1 and blood sugar and recheck them over time. See our post on why doctors check IGF-1.
Sermorelin vs. tesamorelin
Both are GHRH analogs, but their status is very different. Tesamorelin has a current FDA label, large controlled trials and a defined monitoring plan for one specific use. Sermorelin's FDA-approved products are no longer marketed, and current use is mostly compounded and off-label. For an overview of the whole class, see our beginner's guide to GH secretagogues.
Sports and testing
The 2026 WADA Prohibited List names sermorelin as a banned GHRH analog. Tested athletes should not use it without an approved therapeutic use exemption.
Questions to ask before considering it
- What problem are we trying to solve, and is there an FDA-approved option for it?
- Is this compounded, and by what kind of pharmacy?
- What labs will we check before and during use?
- How will we know if it is helping, and when would we stop?
The bottom line
Sermorelin has a real FDA history. It was approved, then discontinued by its maker, with no safety-based withdrawal. Today it has no marketed FDA-approved product in the US, and evidence for anti-aging use in healthy adults is limited. If you are curious, talk with a licensed provider who will check your labs and explain the trade-offs.
Sources
- FDA Federal Register notice: Determination that GEREF (sermorelin acetate) was not withdrawn for safety or effectiveness (2013)
- Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018
- World Anti-Doping Agency: The Prohibited List (2026)
Frequently asked questions
Was sermorelin ever FDA-approved?
Yes. Sermorelin was sold as Geref, approved first as a diagnostic test (1990) and later to treat growth hormone deficiency in children with growth failure (1997). The maker discontinued the products in 2008 and FDA withdrew the approvals effective June 18, 2009.
Was sermorelin pulled for safety reasons?
No. In a 2013 Federal Register notice, FDA determined that Geref products were not withdrawn from sale for reasons of safety or effectiveness. The notice did not state the business reason the maker stopped selling them.
Is there good evidence that sermorelin slows aging?
No strong evidence supports that. Sermorelin's approved history was in children with GH deficiency and in diagnostic testing. Claims about anti-aging, fat loss or muscle gain in healthy adults are not backed by large, modern clinical trials.